Group Zwaan

Medicine & Life Sciences

1. Pediatrics 100%
2. Precursor Cell Lymphoblastic Leukemia-Lymphoma 69%
3. Child 48%
4. Acute Myeloid Leukemia 39%
5. Pharmacokinetics 36%
6. Netherlands 34%
7. Neoplasms 28%
8. Leukemia 26%
9. Inotuzumab Ozogamicin 24%
10. Survival 24%
11. Neuroblastoma 19%
12. Therapeutics 18%
13. Hodgkin Disease 17%
14. Population 16%
15. Dexamethasone 14%
16. Down Syndrome 14%
17. Aprepitant 14%
18. Incidence 13%
19. Chimeric Antigen Receptors 13%
20. Immunotherapy 12%
21. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12%
22. Young Adult 12%
23. Hematopoietic Stem Cell Transplantation 12%
24. Mutation 11%
25. Sleep 11%
26. Clofarabine 10%
27. Hematopoietic Stem Cells 10%
28. Pharmaceutical Preparations 10%
29. Chemokine CCL17 10%
30. Registries 9%
31. Residual Neoplasm 9%
32. T-Lymphocytes 9%
33. 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 9%
34. Medullary Thyroid cancer 8%
35. Mortality 8%
36. Fatigue 8%
37. Recurrence 8%
38. Drug Therapy 7%
39. 5-nitroso-8-quinolinol 7%
40. Vincristine 7%
41. 4-O-deacetyl vinorelbine 7%
42. Preclinical Drug Evaluations 7%
43. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7%
44. Asparaginase 7%
45. Cell- and Tissue-Based Therapy 7%
46. Clinical Trials 7%
47. Cohort Studies 6%
48. United States Food and Drug Administration 6%
49. Progression-Free Survival 6%
50. Non-Hodgkin's Lymphoma 6%
51. Fetal Blood 6%
52. fludarabine 6%
53. Confidence Intervals 6%
54. nelarabine 5%
55. pyrvinium 5%
56. Newborn Infant 5%
57. ribociclib 5%
58. Safety 5%
59. Phenotype 5%
60. Wilms Tumor 5%
61. Drug Monitoring 5%
62. CD19 Antigens 5%
63. Stem Cells 5%
64. DNA methyltransferase 3A 5%
65. ponatinib 5%
66. Oxypurinol 5%
67. atezolizumab 5%
68. Transplantation 5%
69. Topotecan 5%